Somaxon Pharmaceuticals, Inc. (SOMX) Reports Q3 Loss of $0.36,, Sales Fall Short
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Join SI Premium – FREE
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) reported Q3 EPS of ($0.36), $0.05 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $4.55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
